BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor. World J Gastroenterol 2009; 15(46): 5867-5870 [PMID: 19998512 DOI: 10.3748/wjg.15.5867]
URL: https://www.wjgnet.com/1007-9327/full/v15/i46/5867.htm
Number Citing Articles
1
T.W. Barber, M.S. Hofman, B.N.J. Thomson, R.J. Hicks. The potential for induction peptide receptor chemoradionuclide therapy to render inoperable pancreatic and duodenal neuroendocrine tumours resectableEuropean Journal of Surgical Oncology (EJSO) 2012; 38(1): 64 doi: 10.1016/j.ejso.2011.08.129
2
Beata Jabłońska, Daria Dranka-Bojarowska, Hanna Palacz, Adam Lewiński, Paweł Lampe. Surgical Treatment of Pancreatic Neuroendocrine Tumours - Clinical ExperiencePolish Journal of Surgery 2011; 83(4) doi: 10.2478/v10035-011-0033-5
3
Giuseppe Lo Russo, Sara Pusceddu, Natalie Prinzi, Martina Imbimbo, Claudia Proto, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Marco Maccauro, Roberto Buzzoni, Ettore Seregni, Filippo de Braud, Marina Chiara Garassino. Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumorsTumor Biology 2016; 37(10): 12991 doi: 10.1007/s13277-016-5258-9
4
Jaume Capdevila, Enrique Grande, Rocío García-Carbonero, Marc Simó, Mª Isabel del Olmo-García, Paula Jiménez-Fonseca, Alberto Carmona-Bayonas, Virginia Pubul. Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand TherapyThe Oncologist 2022; 27(4): e328 doi: 10.1093/oncolo/oyab041
5
Tessa Brabander, Jaap J.M. Teunissen, Casper H.J. Van Eijck, Gaston J.H. Franssen, Richard A. Feelders, Wouter W. de Herder, Dik J. Kwekkeboom. Peptide receptor radionuclide therapy of neuroendocrine tumoursBest Practice & Research Clinical Endocrinology & Metabolism 2016; 30(1): 103 doi: 10.1016/j.beem.2015.10.005
6
Cyprian Świętaszczyk, Vikas Prasad, Richard P. Baum. Intense 18F-Fluoride Accumulation in Liver Metastases From a Neuroendocrine Tumor After Peptide Receptor Radionuclide TherapyClinical Nuclear Medicine 2012; 37(4): e82 doi: 10.1097/RLU.0b013e3182478a50
7
Richard P. Baum, Harshad R. Kulkarni, Cecilia Carreras. Peptides and Receptors in Image-Guided Therapy: Theranostics for Neuroendocrine NeoplasmsSeminars in Nuclear Medicine 2012; 42(3): 190 doi: 10.1053/j.semnuclmed.2012.01.002
8
M Shah, R Da Silva, C Gravekamp, S K Libutti, T Abraham, E Dadachova. Targeted radionuclide therapies for pancreatic cancerCancer Gene Therapy 2015; 22(8): 375 doi: 10.1038/cgt.2015.32
9
Michael Gabriel. Radiopeptidtherapie – der „Mustang“ in der Therapie von neuroendokrinen Tumoren des gastroentero-pankreatischen Systems?Journal für Klinische Endokrinologie und Stoffwechsel 2018; 11(3): 81 doi: 10.1007/s41969-018-0034-7
10
Nader Hirmas, Raya Jadaan, Akram Al-Ibraheem. Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future PerspectivesNuclear Medicine and Molecular Imaging 2018; 52(3): 190 doi: 10.1007/s13139-018-0517-x
11
Iraklis Perysinakis, Chrysanthi Aggeli, Gregory Kaltsas, George N. Zografos. Neoadjuvant therapy for advanced pancreatic neuroendocrine tumors: an emerging treatment modality?Hormones 2016; 15(1): 15 doi: 10.1007/BF03401399
12
Costanza Chiapponi, Nadine Lürssen, Birgit Cremer, Roger Wahba, Uta Drebber, Michael Faust, Matthias Schmidt, Dirk L. Stippel. Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experienceEndocrine 2020; 70(1): 187 doi: 10.1007/s12020-020-02341-1
13
Hendrik Bergsma, Esther I. van Vliet, Jaap J.M. Teunissen, Boen L.R. Kam, Wouter W. de Herder, Robin P. Peeters, Eric P. Krenning, Dik J. Kwekkeboom. Peptide receptor radionuclide therapy (PRRT) for GEP-NETsBest Practice & Research Clinical Gastroenterology 2012; 26(6): 867 doi: 10.1016/j.bpg.2013.01.004
14
Mila Todorović-Tirnanić, Daniel Kaemmerer, Vikas Prasad, Merten Hommann, Richard P. Baum. Theranostics, Gallium-68, and Other RadionuclidesRecent Results in Cancer Research 2013; 194: 487 doi: 10.1007/978-3-642-27994-2_28
15
Sze Ting Lee, Harshad R. Kulkarni, Aviral Singh, Richard P. Baum. Theranostics of Neuroendocrine TumorsVisceral Medicine 2017; 33(5): 358 doi: 10.1159/000480383
16
Joanne S. Evans, Jamie Beaumont, Marta Braga, Nahal Masrour, Francesco Mauri, Alice Beckley, Shamus Butt, Christina S. Karali, Chris Cawthorne, Stephen Archibald, Eric O. Aboagye, Rohini Sharma. Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapyEuropean Journal of Cancer 2022; 176: 110 doi: 10.1016/j.ejca.2022.09.009
17
Richard P Baum, Harshad R Kulkarni. Molecular Imaging using PET/CT Applying 68Ga-Labeled Tracers and Targeted Radionuclide Therapy: Theranostics on the Way to Personalized MedicineJournal of Postgraduate Medicine, Education and Research 2013; 47(1): 47 doi: 10.5005/jp-journals-10028-1055
18
Sander M. Bison, Mark W. Konijnenberg, Marleen Melis, Stefan E. Pool, Monique R. Bernsen, Jaap J. M. Teunissen, Dik J. Kwekkeboom, Marion de Jong. Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developmentsClinical and Translational Imaging 2014; 2(1): 55 doi: 10.1007/s40336-014-0054-2
19
Francesca Muffatti, Mauro Cives, Stefano Partelli, Franco Silvestris, Massimo Falconi. Neuroendocrine Tumors in Real Life2018; : 235 doi: 10.1007/978-3-319-59024-0_17
20
Andrea Frilling, Irvin M Modlin, Mark Kidd, Christopher Russell, Stefan Breitenstein, Riad Salem, Dik Kwekkeboom, Wan-yee Lau, Catherine Klersy, Valerie Vilgrain, Brian Davidson, Mark Siegler, Martyn Caplin, Enrico Solcia, Richard Schilsky. Recommendations for management of patients with neuroendocrine liver metastasesThe Lancet Oncology 2014; 15(1): e8 doi: 10.1016/S1470-2045(13)70362-0
21
Luca Urso, Alberto Nieri, Ilaria Rambaldi, Angelo Castello, Licia Uccelli, Corrado Cittanti, Stefano Panareo, Irene Gagliardi, Maria Rosaria Ambrosio, Maria Chiara Zatelli, Mirco Bartolomei. Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature reviewEndocrine 2022; 78(2): 255 doi: 10.1007/s12020-022-03170-0
22
Tanaz Vaghaiwalla, Brian Ruhle, Kelvin Memeh, Peter Angelos, Edwin Kaplan, Chih-Yi Liao, Blase Polite, Xavier Keutgen. Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategiesSurgery 2021; 169(1): 162 doi: 10.1016/j.surg.2020.04.001
23
Ryosuke Umino, Satoshi Nara, Noritoshi Kobayashi, Takahiro Mizui, Takeshi Takamoto, Daisuke Ban, Minoru Esaki, Nobuyoshi Hiraoka, Kazuaki Shimada. Pathological complete response of initially unresectable multiple liver metastases achieved using combined peptide receptor radionuclide therapy and somatostatin analogs following pancreatic neuroendocrine tumor resection: a case reportSurgical Case Reports 2024; 10(1) doi: 10.1186/s40792-024-01839-4
24
B. L. R. Kam, J. J. M. Teunissen, E. P. Krenning, W. W. de Herder, S. Khan, E. I. van Vliet, D. J. Kwekkeboom. Lutetium-labelled peptides for therapy of neuroendocrine tumoursEuropean Journal of Nuclear Medicine and Molecular Imaging 2012; 39(S1): 103 doi: 10.1007/s00259-011-2039-y
25
Ashley Kieran Clift, Mark Kidd, Lisa Bodei, Christos Toumpanakis, Richard P. Baum, Kjell Oberg, Irvin M. Modlin, Andrea Frilling. Neuroendocrine Neoplasms of the Small Bowel and PancreasNeuroendocrinology 2020; 110(6): 444 doi: 10.1159/000503721
26
Pamela Moyade, Sobhan Vinjamuri. The heart mattersNuclear Medicine Communications 2019; 40(10): 1081 doi: 10.1097/MNM.0000000000001064
27
Amir Sabet, Hans-Jürgen Biersack, Samer Ezziddin. Advances in Peptide Receptor Radionuclide TherapySeminars in Nuclear Medicine 2016; 46(1): 40 doi: 10.1053/j.semnuclmed.2015.09.005
28
Eric H. Liu, Irvin Modlin. Therapeutic Nuclear MedicineMedical Radiology 2013; : 909 doi: 10.1007/174_2013_808
29
Yongzheng Li, Zhiyao Fan, Feifei Zhang, Jian Yang, Ming Shi, Shujie Liu, Yufan Meng, Hanxiang Zhan. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: A systematic review and meta-analysisFrontiers in Oncology 2022; 12 doi: 10.3389/fonc.2022.981575
30
Mitesh Naik, Adil Al-Nahhas, Sairah R. Khan. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We NowCancers 2022; 14(3): 761 doi: 10.3390/cancers14030761
31
George Barberio Coura-Filho, Mayara Torres Silva de Oliveira, Ana Luiza Morais de Campos. Nuclear Medicine in Endocrine Disorders2022; : 319 doi: 10.1007/978-3-031-13224-7_32
32
Andrea Frilling, Ashley K. Clift. Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum2024; : 31 doi: 10.1007/978-3-031-33533-4_3
33
Sandip Basu, Vikas Ostwal, Rohit Ranade, Dipanjan Panda. Supportive Measures and Finer Practice Points in 177Lu-DOTATATE PRRT for NET: Aiming for Optimal Disease ManagementJournal of Nuclear Medicine 2014; 55(11): 1916 doi: 10.2967/jnumed.114.146282
34
Anna Sowa-Staszczak, Dorota Pach, Robert Chrzan, Małgorzata Trofimiuk, Agnieszka Stefańska, Monika Tomaszuk, Maciej Kołodziej, Renata Mikołajczak, Dariusz Pawlak, Alicja Hubalewska-Dydejczyk. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs)European Journal of Nuclear Medicine and Molecular Imaging 2011; 38(9): 1669 doi: 10.1007/s00259-011-1835-8
35
Rejoice Ngongoni, Brendan Visser. Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver MetastasesCancers 2022; 14(20): 5103 doi: 10.3390/cancers14205103
36
Günter Klöppel, Paul Komminoth, Ph. U. Heitz. Pathologie2016; : 815 doi: 10.1007/978-3-642-04566-0_24
37
Anna Sowa-Staszczak, Robert Chrzan, Dorota Pach, Agnieszka Stefańska, Monika Tomaszuk, Monika Buziak-Bereza, Maciej Kołodziej, Elwira Przybylik-Mazurek, Alicja Hubalewska-Dydejczyk. Are RECIST criteria sufficient to assess response to therapy in neuroendocrine tumors?Clinical Imaging 2012; 36(4): 360 doi: 10.1016/j.clinimag.2011.11.005
38
Dik J. Kwekkeboom, Eric P. Krenning. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine TumorsHematology/Oncology Clinics of North America 2016; 30(1): 179 doi: 10.1016/j.hoc.2015.09.009
39
Marianne Pavel, Eric Baudin, Anne Couvelard, Eric Krenning, Kjell Öberg, Thomas Steinmüller, Martin Anlauf, Bertram Wiedenmann, Ramon Salazar. ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown PrimaryNeuroendocrinology 2012; 95(2): 157 doi: 10.1159/000335597
40
Tak Geun Oh, Moon Jae Chung, Jeong Yeop Park, Seung Min Bang, Seung Woo Park, Jae Bok Chung, Si Young Song. Prognostic Factors and Characteristics of Pancreatic Neuroendocrine Tumors: Single Center ExperienceYonsei Medical Journal 2012; 53(5): 944 doi: 10.3349/ymj.2012.53.5.944
41
Daniel Kaemmerer, Ralph M. Wirtz, Elke K. Fischer, Merten Hommann, Jörg Sänger, Vikas Prasad, Elisa Specht, Richard P. Baum, Stefan Schulz, Amelie Lupp. Analysis of Somatostatin Receptor 2A Immunohistochemistry, RT-qPCR, and In Vivo PET/CT Data in Patients With Pancreatic Neuroendocrine NeoplasmPancreas 2015; 44(4): 648 doi: 10.1097/MPA.0000000000000316
42
Jordan M. Cloyd, Kiyohiko Omichi, Takashi Mizuno, Yoshikuni Kawaguchi, Ching-Wei D. Tzeng, Claudius Conrad, Yun Shin Chun, Thomas A. Aloia, Matthew H. G. Katz, Jeffrey E. Lee, Daniel Halperin, James Yao, Jean-Nicolas Vauthey, Arvind Dasari. Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver MetastasesAnnals of Surgical Oncology 2018; 25(6): 1709 doi: 10.1245/s10434-018-6468-8
43
S. Gül-Klein, R. Schmuck, D. P. Modest, J. Pratschke. Therapie kolorektaler und nichtkolorektaler Lebermetastasen: Sinnhaftigkeit neoadjuvanter TherapiekonzepteDer Chirurg 2020; 91(5): 396 doi: 10.1007/s00104-020-01133-7
44
Hina J. Shah, Evan Ruppell, Rozan Bokhari, Parag Aland, Vikram R. Lele, Connie Ge, Lacey J. McIntosh. Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative reviewEuropean Journal of Radiology Open 2023; 10: 100477 doi: 10.1016/j.ejro.2023.100477
45
Anna Sowa-Staszczak, Alicja Hubalewska-Dydejczyk, Monika Tomaszuk. Theranostics, Gallium-68, and Other RadionuclidesRecent Results in Cancer Research 2013; 194: 479 doi: 10.1007/978-3-642-27994-2_27
46
Mauro Cives, Jonathan Strosberg. Radionuclide Therapy for Neuroendocrine TumorsCurrent Oncology Reports 2017; 19(2) doi: 10.1007/s11912-017-0567-8
47
Andrea Lania, Francesco Ferraù, Manila Rubino, Roberta Modica, Annamaria Colao, Antongiulio Faggiano. Neoadjuvant Therapy for Neuroendocrine Neoplasms: Recent Progresses and Future ApproachesFrontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.651438
48
Marco Schiavo Lena, Stefano Partelli, Paola Castelli, Valentina Andreasi, Chanel Elisha Smart, Eleonora Pisa, Mirco Bartolomei, Emilio Bertani, Giuseppe Zamboni, Massimo Falconi, Claudio Doglioni. Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT)Endocrine Pathology 2020; 31(2): 119 doi: 10.1007/s12022-020-09623-4
49
Richard P. Baum, Harshad R. Kulkarni. Therapeutic Nuclear MedicineMedical Radiology 2014; : 583 doi: 10.1007/174_2013_945
50
Wouter A van der Zwan, Lisa Bodei, Jan Mueller-Brand, Wouter W de Herder, Larry K Kvols, Dik J Kwekkeboom. GEP–NETs UPDATE: Radionuclide therapy in neuroendocrine tumorsEuropean Journal of Endocrinology 2015; 172(1): R1 doi: 10.1530/EJE-14-0488
51
Esther I. van Vliet, Casper H. van Eijck, Ronald R. de Krijger, Elisabeth J. Nieveen van Dijkum, Jaap J. Teunissen, Boen L. Kam, Wouter W. de Herder, Richard A. Feelders, Bert A. Bonsing, Tessa Brabander, Eric P. Krenning, Dik J. Kwekkeboom. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]OctreotateJournal of Nuclear Medicine 2015; 56(11): 1647 doi: 10.2967/jnumed.115.158899
52
K.L. Pomykala, B.A. Hadaschik, O. Sartor, S. Gillessen, C.J. Sweeney, T. Maughan, M.S. Hofman, K. Herrmann. Next generation radiotheranostics promoting precision medicineAnnals of Oncology 2023; 34(6): 507 doi: 10.1016/j.annonc.2023.03.001
53
Simone Krebs, Mark Dunphy. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set2017; : 285 doi: 10.1016/B978-0-323-34062-5.00017-0
54
Ashley K. Clift, Henk Giele, Srikanth Reddy, Rubens Macedo, Adil Al-Nahhas, Harpreet S. Wasan, Gabriel E. Gondolesi, Rodrigo M. Vianna, Peter Friend, Anil Vaidya, Andrea Frilling. Neoadjuvant peptide receptor radionuclide therapy and modified multivisceral transplantation for an advanced small intestinal neuroendocrine neoplasm: an updated case reportInnovative Surgical Sciences 2017; 2(4): 247 doi: 10.1515/iss-2017-0025
55
Sandip Basu, Rahul V. Parghane, Vikas Ostwal, Shailesh V. Shrikhande. Neoadjuvant strategies for advanced pancreatic neuroendocrine tumorsNuclear Medicine Communications 2018; 39(1): 94 doi: 10.1097/MNM.0000000000000776
56
Daniel Kaemmerer, Vikas Prasad, Wolfgang Daffner, Sven-Petter Haugvik, Stefan Senftleben, Richard P. Baum, Merten Hommann. Radioguided Surgery in Neuroendocrine Tumors Using Ga-68-Labeled Somatostatin AnalogsClinical Nuclear Medicine 2012; 37(2): 142 doi: 10.1097/RLU.0b013e3182291de8
57
Kelsey L. Pomykala, Ken Herrmann. Radiopharmaceutical Therapy2023; : 3 doi: 10.1007/978-3-031-39005-0_1
58
Deborah Pencharz, Gopinath Gnanasegaran, Shaunak Navalkissoor. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapyThe British Journal of Radiology 2018; 91(1091): 20180108 doi: 10.1259/bjr.20180108
59
Andrea Frilling, Ashley K. Clift. Therapeutic strategies for neuroendocrine liver metastasesCancer 2015; 121(8): 1172 doi: 10.1002/cncr.28760
60
Claudia Burkhardt, Léo Bühler, David Viertl, Thierry Stora. New Isotopes for the Treatment of Pancreatic Cancer in Collaboration With CERN: A Mini ReviewFrontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.674656
61
James R. Howe, Nipun B. Merchant, Claudius Conrad, Xavier M. Keutgen, Julie Hallet, Jeffrey A. Drebin, Rebecca M. Minter, Terry C. Lairmore, Jennifer F. Tseng, Herbert J. Zeh, Steven K. Libutti, Gagandeep Singh, Jeffrey E. Lee, Thomas A. Hope, Michelle K. Kim, Yusuf Menda, Thorvardur R. Halfdanarson, Jennifer A. Chan, Rodney F. Pommier. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine TumorsPancreas 2020; 49(1): 1 doi: 10.1097/MPA.0000000000001454
62
Ashley Kieran Clift, Andrea Frilling. Management of patients with hepatic metastases from neuroendocrine tumorsAnnals of Saudi Medicine 2014; 34(4): 279 doi: 10.5144/0256-4947.2014.279
63
Ashley Kieran Clift, Andrea Frilling. Neuroendocrine Tumors2021; : 267 doi: 10.1007/978-3-030-62241-1_17
64
S. Nadalin, M. Peters, A. Königsrainer. Lebermetastasen neuroendokriner TumorenDie Chirurgie 2022; 93(7): 659 doi: 10.1007/s00104-022-01656-1
65
Isabella Zanata, Maria Rosaria Ambrosio, Maria Chiara Zatelli. Neoadjuvant PRRT for advanced pNEN: an unusual highlanderEndocrine 2021; 73(2): 493 doi: 10.1007/s12020-021-02662-9
66
Daniel Kaemmerer. Beyond Becquerel and Biology to Precision Radiomolecular Oncology: Festschrift in Honor of Richard P. Baum2024; : 177 doi: 10.1007/978-3-031-33533-4_17